Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

1(100.0%)

1Total

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT04147832Completed

Epividian / AHF: Positive Pathways - HIV Retention in Care

Role: lead

NCT03813862Recruiting

Observational Pharmaco-Epidemiology Research & Analysis

Role: lead

NCT04863261Not ApplicableCompleted

Cabenuva Injection Tracking in CHORUS

Role: lead

NCT05710120Completed

Hepatitis C Screening Alerts

Role: lead

NCT05725109Completed

Hepatitis C Diagnosis to Treatment Management

Role: lead

NCT05495204Completed

External Comparison of Ibalizumab in Trials vs. Other Regimens in OPERA

Role: lead

NCT05104359Completed

COVID-19 Quantitative Antibody Titers & Booster Vaccinations

Role: lead

NCT03584048Completed

Charlotte Retention in Care Study

Role: lead

All 8 trials loaded